Investment Thesis
Amarin is a cash-draining pharmaceutical company with declining revenue (-6.5% YoY) and severe operating losses (-25.1% margin), indicating fundamental business challenges in a highly competitive sector. While the fortress balance sheet ($131M cash, zero debt) provides survival runway, the absence of profitability trajectory or growth signals makes capital preservation the priority until commercial inflection becomes evident.
Strengths
- Fortress balance sheet with $131M cash and zero long-term debt providing financial flexibility
- Positive free cash flow ($6.1M) despite net losses shows management controls burn rate effectively
- Strong liquidity ratios (3.48x current, 2.46x quick) ensure no near-term solvency risk
Risks
- Revenue declining 6.5% YoY signaling product demand erosion or market share loss in competitive pharma landscape
- Deep operating losses (-$11.3M) and negative net margin (-23.3%) indicate business model is not self-sustaining
- Pharma sector requires continuous pipeline success; no evidence of blockbuster products or growth catalysts offsetting declines
Key Metrics to Watch
- Revenue stabilization and gross margin sustainability as indicators of product-market fit recovery
- Operating margin trajectory toward profitability; path to cash flow breakeven critical
- Cash runway calculation relative to burn rate; monitor when cash reserve drops below 18-month operating expense threshold
Financial Metrics
Revenue
45.1M
Net Income
-10.5M
EPS (Diluted)
$-0.03
Free Cash Flow
6.1M
Total Assets
645.8M
Cash
131.1M
Profitability Ratios
Gross Margin
39.4%
Operating Margin
-25.1%
Net Margin
-23.3%
ROE
-2.3%
ROA
-1.6%
FCF Margin
13.6%
Balance Sheet & Liquidity
Current Ratio
3.48x
Quick Ratio
2.46x
Debt/Equity
0.00x
Debt/Assets
30.4%
Interest Coverage
-1,619.14x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T14:20:49.999080 |
Data as of: 2026-03-31 |
Powered by Claude AI